GLP-1 Receptor Agonists Linked to Reduced Risk of Legal Blindness in Type 2 Diabetes

Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may experience a significantly lower risk of legal blindness, according to a retrospective cohort study published in Clinical Ophthalmology [1]. The study, utilizing data from over 70 healthcare organizations across the United States, found no significant association between GLP-1 RA use and an increased risk of ischemic optic neuropathy (ION).

Study Details and Methodology

Researchers analyzed de-identified electronic medical record (EMR) data from TriNetX, spanning January 2018 to January 2025. The cohort included adults aged 18 years or older with T2DM, an A1c level below 10%, and at least one cardiovascular risk factor – hyperlipidemia, essential hypertension, overweight/obesity, or chronic ischemic heart disease. Patients were divided into two groups: those prescribed a GLP-1 RA and those who were not.

After employing propensity score matching (PSM), both groups comprised 350,536 patients (average age 58.7 years, 61.6% female). The analysis revealed a significantly reduced risk of legal blindness at 1 year (HR 0.589, 95% CI 0.476–0.728), 3 years (HR 0.677, 95% CI 0.583–0.788), and 5 years (HR 0.669, 95% CI 0.583–0.768) among those using GLP-1 RAs [1].

Implications and Potential Benefits

As GLP-1 RAs become increasingly prevalent in the management of T2DM and obesity, particularly in patients with cardiovascular comorbidities, the study suggests potential ancillary ophthalmic benefits beyond glycemic and cardiovascular control [1]. Researchers believe these findings could inform discussions between clinicians and patients regarding the ocular safety profile of GLP-1 receptor agonists in individuals with T2DM and elevated vascular risk.

Ischemic Optic Neuropathy (ION) Findings

The study did not find a significant difference in the incidence of ION between the GLP-1 RA group and the control group at any time point (1 year: HR 0.872, 95% CI 0.627–1.212; 3 years: HR 1.002, 95% CI 0.792–1.268; 5 years: HR 0.978, 95% CI 0.789–1.211) [1].

Study Limitations

The researchers acknowledged several limitations, including the retrospective study design, incomplete 5-year follow-up data for some patients, the absence of baseline visual acuity data, and the inability to assess cumulative GLP-1 RA exposure, dosage, or medication adherence. One study author disclosed affiliations with biotech, pharmaceutical, and/or device companies [1].

GLP-1 RAs and Diabetic Retinopathy

Recent research indicates a complex relationship between GLP-1 RAs and ophthalmic complications. While this study focuses on legal blindness and ION, other research suggests a potential association between GLP-1 RAs and an increased risk of diabetic retinopathy (DR) [3]. Further investigation is needed to fully understand these varying effects.

Growing Use of GLP-1 RAs

The increasing use of GLP-1 RAs for both type 2 diabetes and weight management is driving further research into their broader health effects [4]. A study published in January 2026 showed that patients with type 2 diabetes prescribed GLP-1 RAs had a reduced risk of legal blindness [2].